Navigation Links
Boosting Pharma Sales Force Effectiveness through Streamlined Internal Communications
Date:12/12/2007

CHAPEL HILL, N.C., Dec. 12 /PRNewswire/ -- The success of a pharmaceutical sales force is built on effective communication. Yet ineffective internal communication between sales reps and regional corporate sources are eating into reps' time on the job, according to a new study by benchmarking leader Best Practices, LLC.

Pharma sales reps spend an average of 13.7 hours a week managing internal communication and, of that, 4.4 hours (or 32 percent) are perceived as unnecessary, according to the study. Most of those 4.4 hours is made up of email and cell phone communications and a vast majority of the communications comes from regional and local sources, according to the study. Sales reps estimate they receive more than 150 email and voicemail communications a week from regional sources.

Pharmaceutical companies could increase sales staff productivity by more than 10 percent by eliminating unnecessary internal communications to the field, according to the study. To learn more about this report, Pharma Sales Force Effectiveness: Increasing Productivity Through Streamlined Internal Communication, please download a complimentary report excerpt and study overview at http://www3.best-in-class.com/rr890.htm

The research is based on interviews and benchmarking surveys from 10 leading pharmaceutical and biotech companies, including Pfizer, Eli Lilly, Genentech, Johnson & Johnson and Merck. Executives and managers who oversee sales operations can use this study to improve the productivity of their field sales force.

The research findings from this study highlight significant costs of unnecessary communication across a direct sales force as well as the best practices that sales communications functions, district managers, sales reps and IT managers can use to help prevent unnecessary internal communication.

Some of the key topics covered in the report include:

-- Total time spent on internal communication

-- Percentage of unnecessary time spent

-- Costs of unnecessary communication

-- Most effective communication methods

To learn more about this report, including key findings and sample best practices, download a complimentary excerpt at: http://www3.best-in- class.com/rr890.htm .

For questions or additional information on Best Practices, LLC's other products and services, please call Cameron Tew at 919-767-9246 or email ctew@best-in-class.com. Also, visit our Web site at: http://www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call 919-403-0251 or visit http://www3.best-in-class.com/.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Schools Getting Better at Boosting Kids Health
2. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia ... A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude ... pair observed that when photosynthetically active radiation (i.e. the white light in our ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... organization, announces McLaughlin & Smoak Benefits as the latest addition to its family ... has a dedicated team of compliance, wellness, human resources, and health care consumerism ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... compensation laws in all U.S. states and certain Canadian provinces is now available ... Workers Compensation Research Institute (WCRI). , The report, Workers’ Compensation Laws ...
(Date:5/5/2016)... ... ... A recent survey by the Midwest Business Group on Health ... use the free preventive care benefits available to them as part of the Affordable ... public and private employers, MBGH found that only 10% of large employers are aware ...
(Date:5/5/2016)... TX (PRWEB) , ... May 05, 2016 , ... Vitenas ... AIA/AAH Healthcare Design Awards, presented by the American Institute of Architects and the Academy ... designed by the renowned Perkins+Will and Harrell Architects, opened to patients in October of ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
(Date:5/3/2016)... 3, 2016  While you may be familiar with watching a film or TV show in ... ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
Breaking Medicine Technology: